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Executive Summary
Three discussion papers about the design and evaluation of a trial to provide heroin to dependent users
in a controlled manner are presented. They raise a number of difficult issues that need to be taken into
consideration before the trial design can be finalised.
The first is a report on a workshop on trial evaluation held in June 1993. The bulk of the discussion
involved the advantages and disadvantages of three evaluation designs: the randomised controlled trial
design, a modified randomised controlled trial design, and the cross–over design. The types of
comparisons that could be incorporated in these designs were also discussed. It was agreed that oral
methadone would be the ‘control’ group. This could be compared with injectable heroin, or injectable
heroin plus oral methadone, or with a group which had a range of choices between heroin and/or
methadone and injectable, oral and smokable routes of administration. The impact of choice of study
population on the generalisability of the results and on the types of outcome measures that could be used
was also discussed. While there was little support for non–experimental designs, discussion of such
designs clarified the limitations of the experimental approaches.
The second paper involves the statistical consideration of alternative trial designs in the case where
participants can elect not to be allocated to certain treatments. It was shown that this necessarily leads to
a loss of power, but that substantial improvements can be made over the ‘intention to treat’ analysis.
Given the scenario of three possible treatments— heroin only, heroin plus methadone, and methadone
only— and the likelihood that some participants will not accept allocation to treatment with methadone
only, two possibilities for allocation were explored. The first was to ask, before allocation to a treatment,
whether or not participants would continue to participate if they were allocated to the methadone only
treatment. Those who would continue to participate would then be randomly allocated to one of the three
possible groups; those who would not would be randomly allocated to either heroin only or heroin plus
methadone. The second possibility would be to randomly allocate participants to one of the three arms
initially, then to ask those allocated to the methadone only arm whether or not they would continue to
participate. If not, they would be randomly re–allocated to either heroin only or heroin plus methadone.
Statistically, the first design has clear advantages over the second. This was the design considered as the
modified randomised controlled trial design in the workshop reported in the first paper.
The third discussion paper deals with potential conflicts between the provision of an effective service to
participants in a ‘heroin trial’ and the constraints that may be imposed by the need for rigorous
evaluation. In particular, the incompatibilities between a health development approach to service
provision and a randomised controlled trial are explored. Two issues that are especially important, and
that are a good illustration of the difficulties, are client choice and individualised treatment. A set of
principles of practice is identified.
The design and evaluation of a trial of controlled provision of heroin to dependent users is an important
part of the feasibility considerations. As the three discussion papers illustrate, there are many difficulties
that will need to be resolved for a trial to go ahead. The final considerations about trial design and
evaluation will also need to include information gathered in other components of the feasibility study
about numbers of dependent heroin users in Canberra, possible outcome measures and the preferences of
potential trial participants.
Foreword
In our considerations about a trial to provide heroin in a controlled manner to dependent users, the
necessity for rigorous evaluation has always been at the forefront (Douglas 1991; Bammer 1993). In our
ongoing discussions about trial design and evaluation, we have also developed a number of other criteria
that a trial should meet. Thus, a trial should be
• rigorous and able to give clear answers to definitive questions;
• acceptable to potential participants;
• congruent with a health development approach to service provision;
• ethical; and
• generalisable.
Designing a trial to meet these criteria is one of the most difficult aspects of the feasibility considerations.
In this working paper, three discussion papers are presented, which in different ways engage some of the
complex issues involved in trial design and evaluation.
In Stage 1 of the feasibility considerations, a range of design and evaluation strategies were considered
(Bammer et al. 1991) and it was concluded that a randomised controlled trial was likely to be the best
design for an experiment with the controlled provision of heroin to dependent users in Canberra. The
‘experimental group’ would have a choice of treatments between heroin and/or methadone and
injectable, oral and/or smokable routes of administration. They would be compared to a group that
received oral methadone only. The questions a trial would seek to address would be:
“Can a treatment program which offers heroin (as well as methadone) and injectable and smokable
routes of administration (as well as oral) increase the likelihood that participants will be able to:
a. lead a more structured lifestyle in terms of employment, relationships and day–to–day activity?
b. reduce their criminal activity?
c. reduce behaviours that place them at risk of contracting HIV and hepatitis B and C?
d. increase behaviours important in the maintenance of health and well–being?” (Bammer et al.,
1991).
Potential problems with a high rate of drop–outs amongst participants allocated to the group receiving
only oral methadone were recognised. This had occurred in the only previous randomised controlled trial
comparing heroin and methadone maintenance treatments. In a study conducted in the late 1970s, the
then new treatment option, oral methadone, was compared with injectable heroin, which was at that time
the standard maintenance treatment in the United Kingdom (Hartnoll et al., 1980). Twelve percent of
participants allocated to receive oral methadone dropped–out immediately; by three months less than 50
percent were still in the trial and by 12 months only 29 percent of the original participants remained in
the oral methadone group. At 12 months, 74 percent of those allocated to receive injectable heroin were
still in the trial. This potential problem with drop–outs piqued the interest of NCEPH statistician, Dr
Patty Solomon, who began work on possible modifications to a randomised controlled trial that would
allow participants some choice. When she moved to the University of Adelaide, Professor Richard Jarrett
joined her in that preliminary research, the results of which are presented here as the second discussion
paper.
At the same time, a small group of NCEPH and AIC researchers (Gabriele Bammer, David Legge, David
McDonald and Beverly Sibthorpe) met on a monthly basis to discuss the limitations of a randomised
controlled trial on the interactions between clinical trial staff and trial participants. The group was
particularly influenced by the work of one of its members (David Legge) on health development, and
potential incompatibilities between a health development approach to service provision in a trial and a
randomised controlled trial were explored. The group read and discussed a number of articles and books,
particularly about cultural attitudes to pleasure and the significance of different explanatory models of
drug use in shaping models of service delivery; considered their own experiences and the experiences of
guests to the group (service providers and illicit drug users) with drug treatment and prevention
agencies; and developed a set of principles that might underlie the service provision in a ‘heroin trial’,
including testing these principles in a range of scenarios. A distillation from these discussions is
presented as the third paper.
Both the second and third discussion papers were provided as background reading for the June 1993
workshop. At that workshop, there was very little discussion about the issues raised in the third paper.
The design and evaluation of a trial of controlled provision of heroin to dependent users is an important
part of the feasibility considerations. As the three discussion papers illustrate, there are many difficulties
that will need to be resolved for a trial to go ahead. The final considerations about trial design and
evaluation will also need to include information gathered in other components of the feasibility study
about numbers of dependent heroin users in Canberra, possible outcome measures and the preferences of
potential trial participants. We expect to be in a position to make a final decision about trial design and
evaluation in May 1994 and would welcome responses to this working paper for consideration.
Gabriele Bammer
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REPORT ON A WORKSHOP ON TRIAL EVALUATION
Gabriele Bammer* and David McDonald#
* National Centre for Epidemiology and Population Health
# Australian Institute of Criminology
Summary
The workshop discussion focussed on five issues: the definition of the study population, the
types of comparisons which could be made, possible experimental designs, outcome measures
and non–experimental designs. The bulk of the discussion involved detailed consideration of
three experimental designs: the randomised controlled trial design, a modified randomised
controlled trial design as proposed by Jarrett and Solomon and the cross–over design. The
strengths and weaknesses of each were discussed. The discussion highlighted many of the
difficulties inherent in trial design and evaluation. The design and evaluation cannot be
finalised until research investigating numbers of potential participants and workable outcome
measures is finalised.
1 Introduction
In June 1993, a workshop about the evaluation of a trial to provide heroin to dependent users in a
controlled manner was held. It aimed to build on earlier considerations about the evaluation (Bammer
1993; Bammer et al. 1991; Ostini et al. 1993) and to incorporate new research (Jarrett and Solomon,
accompanying; McDonald et al., accompanying). A list of workshop participants is included at the end of
this paper. The papers listed as references were provided as preliminary background reading.
The discussion was wide–ranging and fairly unstructured and, to some extent, that is reflected in this
report. Very little time was spent discussing the precise research question. The gist of the question posed
in Stage 1 was used as a general starting point. It was recognised that the precise question would finally
be determined by an interplay between questions of interest, the evaluation design and possible outcome
measures. To reiterate, the question posed in Stage 1 was:
“Can a treatment program which offers heroin (as well as methadone) and injectable and smokable
routes of administration (as well as oral) increase the likelihood that participants will be able to:
a. lead a more structured lifestyle in terms of employment, relationships and day–to–day activity?
b. reduce their criminal activity?
c. reduce behaviours that place them at risk of contracting HIV and hepatitis B and C?
d. increase behaviours important in the maintenance of health and well–being?” (Bammer et al.
1991).
2 The study population – people who want treatment or people who want
heroin?
It was agreed early in the workshop that the population eligible to participate in a trial needed to be
specified. Dependent heroin users can be divided into those who want to participate because they are
interested in treatment and those who wish to participate because they are interested in easier, safer
access to heroin. Because the motivations of these two groups are different, the outcomes of their
participation may also be different. In addition, choice of study population will determine how the trial is
run and the generalisability of the results.
The discussion at the workshop defined the population eligible for the trial to be people who are willing
to enter a treatment program for their heroin use. On this basis, it was considered that people currently
on the Canberra methadone program could be the starting population to be offered a place on a ‘heroin
trial’. A place on a trial could also be offered to new recruits to the methadone program for a specified
period of time. Thus, eligible people would be told about the trial and invited to participate. Some would
refuse. Those who gave informed consent would then be randomly allocated to one of two or three
groups, which would then be compared on a number of outcome measures using one of the experimental
designs outlined below. The following discussion outlines groups that could be compared, potential
experimental designs and potential outcome measures. There is also a brief discussion of non–
experimental designs.
3 Comparisons between groups
It is possible to identify a number of comparisons between groups that could be appropriate for any of
the experimental designs discussed below. They include the following:
• choice of treatments (including heroin and/or methadone with injectable, smokable and/or oral
routes of administration) versus no choice (oral methadone only). This was the comparison proposed
at the end of Stage 1 (Bammer et al. 1991);
• injectable heroin versus oral methadone;
• injectable heroin versus injectable heroin plus oral methadone versus oral methadone (3 groups);
• injectable heroin plus oral methadone versus oral methadone;
• injectable heroin plus oral methadone versus oral methadone versus injectable methadone (3 groups).
In each comparison, oral methadone is the ‘control’ group. It was noted that, depending on the precise
nature of the research question, an arm that contains heroin only rather than a choice of treatments may
have more statistical power for comparison with oral methadone because it is more homogeneous.
For the purposes of illustration, the comparison between injectable heroin, injectable heroin plus oral
methadone, and oral methadone will be used in all the examples given below and the starting population
will be assumed to be people currently on the methadone program.
4 Standard randomised controlled trial design
People currently 
on the 
methadone 
program
informed 
consent, 
then 
random 
allocation
refusal to 
participate
injectable heroin
injectable heroin 
plus 
oral methadone
oral methadone
Advantages*
• simplicity and clarity;
• dropping–out of the trial is an outcome measure that is easy to obtain;
• compared with the cross–over trial design, people are not artificially held in the trial;
• compared with a cross–over design, there is less problem with the need to keep people in a trial for
long enough to be able to unequivocally associate outcomes with treatments (see below);
• strong external validity, that is, the RCT design is considered by many people, including those who
advise decision makers, to be the gold standard for evaluating a new intervention.
Disadvantages
• may not be acceptable to participants;
• if high drop–out rates are expected, it may be unethical for a trial to be established primarily to
measure dropping–out of the trial as an outcome;
• if there are differences between the two groups in the numbers dropping out, there will be difficulties
in measuring other outcomes that rely on self–report;
• to obtain accurate information on self–report outcomes, people who have dropped out of the trial will
need to be found and followed up. This is expensive and time–consuming;
• works best with independent outcome measures, for example, crime rates measured by the police or
overdose data collected in hospitals. In Australia, there are no well–established reliable data sets for
either health or criminal outcome measures. In addition, obtaining such data for individuals who
agree to participate in a trial may be expensive, time–consuming and difficult because of privacy
considerations;
• a high drop–out rate, especially if not evenly distributed between the different groups in the trial, will
adversely affect the power of the study.
Other points
There was some debate about whether or not this was the best design for generalising results to policy.
Results from randomised controlled trials can be well generalised to policy if comparisons are made
between communities rather than individuals, and thus where communities rather than individuals are
subjected to random allocation to different ‘treatments’. Lawrence Sherman pointed to his experience
with studies of responses to domestic violence in this context (Sherman 1992). In the example given
                                                       
* many of the advantages and disadvantages apply to more than one of the designs, but they have not always been
reiterated for each design.
above, the results could be generalised to people in a treatment program with conditions similar to those
in a trial, but would not be relevant to the needs of heroin users in the community generally. (This is also
the case for the examples given in the other designs.)
5 Modified Randomised Controlled Trial Design
One of the designs from the accompanying paper by Jarrett and Solomon was discussed in detail. It
should be noted that this design was originally conceived for a different scenario where any dependent
heroin user could apply for a place on a trial— in other words, it was not restricted to people on the
methadone program.
People currently 
on the methadone 
program
informed  
consent 
and accept  
possibility 
of methadone 
only
refusal to  
participate
YES 
random 
allocation
NO 
random 
allocation
injectable heroin 
injectable heroin plus 
oral methadone 
oral methadone
injectable heroin
injectable heroin plus 
oral methadone
The first decision is that people would be asked if they agree to participate in an arm where they might be
allocated to receive either injectable heroin only, injectable heroin plus oral methadone or oral methadone
only. Essentially, this arm is the same as a standard randomised controlled trial. Participants who do not
agree to participate in this arm could fall into one of two groups, those who will only participate if they
receive heroin and those who will only participate if they receive methadone (this last case was not
considered by Jarrett and Solomon). The first group could be assigned to heroin only or heroin plus
methadone (shown above); the second group could be assigned to methadone only or methadone plus
heroin (not shown).
Advantages
• offers a technical advantage over simply letting people drop–out if they do not accept the arm to
which they are randomly allocated;
• fits more closely to a health development approach to service provision, because the process of
allocating participants to a ‘control’ group is more responsive to the needs of the individual par-
ticipants than a standard RCT design can be;
• likely to have better client acceptability and therefore higher recruitment and retention levels.
Disadvantages
• if a high proportion refuse to participate in the arm that is essentially the standard RCT, the trial will
have low public acceptability and low generalisability (external validity);
• giving people this choice may increase the likelihood that they will not accept something they would
have accepted if there was no choice;
• design rests on more assumptions than the standard RCT;
• design is more complicated than the standard RCT;
• would not allow research questions concerning retention in treatment to be addressed.
6 Cross–over design
The time period for the cross–over needs to be determined in light of the outcomes to be measured, but
for the sake of this example 6 months is used. Participants would be randomly allocated to one of three
groups and would stay in this group for 6 months, at which time they would swap to a second group. At
the end of a further 6 months, participants would swap to a third group. The trial could finish 6 months
after the swap to the third group or could have a final stage where participants were allowed a free choice
of any group for 6 months. This is represented diagramatically below.
People currently 
on the methadone 
program, 
informed 
consent, 
random  
allocation
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Advantages
• people are less likely to drop–out than in a standard RCT, so that the different options can be more
easily compared on a range of outcome measures; thus this is a good design for self–reported outcome
measures;
• eliminates reallocation and associated difficulties with the modified RCT;
• this is the best design when amelioration rather than cure is expected and when modest incremental
effects are expected.
Disadvantages
• would not allow research questions concerning retention in treatment to be addressed;
• people transferring from a group that has methadone as one of its treatments to a group that does not
may have effects caused by withdrawing from methadone (the effects of methadone are more long–
lasting than those of heroin);
• the time needed to measure outcomes reliably may become unacceptably long. Outcomes relating to
health status, social functioning, criminal behaviour and so on take time to develop, and the time in
each treatment group would need to be long enough to clearly relate the outcome to the treatment and
to ensure that it was not a carry–over effect from the previous treatment;
• usually cross–over is done with people who are ‘blind’ to the treatment, but that is clearly not possible
here;
• no allowance is made for client choice, as is the case with the modified randomised controlled trial
design
Other points
A possible source of bias comes from the likelihood that some (probably many) of the trial participants
will enrol primarily to receive heroin. This could mean that those allocated to the heroin option in the
first stage may drop out when that stage concludes, whereas those allocated to the non–heroin option
first may be motivated to remain on the program because of the incentive of transferring to the heroin
option later. This is an argument for including a free choice option as the last stage of the trial. This also
highlights the importance of determining (if possible) if dropping–out of the trial was planned by
participants (as in the case where trial participants only remain on the trial as long as they are in a
particular group) or ‘impulsive’, in other words motivated by other factors.
7 Outcome Measures
Workshop participants agreed that deciding upon the outcome measures is a prerequisite to making final
decisions about trial design. A central issue is whether the measures should focus upon the individual
trial participants, be at the community level, or both. The usual approach is to restrict the outcome
measures to indicators of the functioning of the individual trial participants, including, where possible,
trial drop–outs. Public policy considerations in the case of this study, however, suggest that community–
level outcome measures are also relevant. For example, significant decision–makers could well be
interested in ascertaining whether or not a trial would cause a reduction in Canberra’s crime rate.
The degree to which trial–induced changes among individual participants would be reflected in
aggregate community–wide statistics would depend upon the proportion of Canberra’s heroin users who
participated in the trial and upon the degree to which their behaviour contributed to the aggregate
measures. For example, the authorities do not have, and do not expect to have, data on the proportion of
Canberra’s property crime that is currently committed by illicit drug users. It is impossible to anticipate,
then, what community–level changes in property crime could be observed from a successful trial.
Three broad approaches are available for collecting outcome data relating to individual trial participants
(including drop–outs), namely:
• self–reported data;
• information on individuals which is gathered from others who are in contact with them; and
• surveillance data (that is, data which are administrative by–products collected by official agencies).
The sorts of information on participants that could be collected from self reports and from people who
are in contact with participants include:
• licit and illicit drug use (this could be complemented by objective measures such as urine tests or hair
analysis);
• criminal behaviour;
• health;
• social functioning;
• HIV risk behaviour;
• etcetera.
The sorts of information that could be collected through surveillance include:
• arrests, convictions and court dispositions;
• admission to hospital accident and emergency units;
• ambulance attendance at drug overdoses;
• access to medical treatment;
• etcetera.
Clearly, significant privacy considerations are involved here. The matter would need to be approached in
a number of ways, including through the informed consent of trial participants, close cooperation
between researchers and official agencies and, possibly, through an approach to the Commonwealth
Privacy Commissioner. The Australian Capital Territory Epidemiological Studies (Confidentiality) Act, which
currently covers the Feasibility Research, facilitates the protection of privacy.
A range of other outcome measures could also be relevant. They include the following:
• drop–out or retention. As discussed above, the level of retention may be affected by the design
employed, that is, some designs may be more attractive than others, better attuned to the needs of the
participants and potential participants. Drop–out or retention is likely to be less of an issue if trial
participants are recruited from among the clients of the methadone program (where being allocated to
the control group would be the same as the treatment they were currently receiving), than if any
dependent heroin users were eligible to participate. In this case though, using drop–out or retention as
an outcome measure may have limited value, because the already high retention rate of methadone
programs means that only limited scope exists for improvement through the use of the alternatives
envisioned for a trial. This has implications in terms of the capacity of the design (especially the
number of participants) to identify statistically significant differences in retention levels between the
different groups in the trial;
• attracting participants who were not previously in touch with drug–related services. This outcome
measure could not be used if eligibility for trial participation was restricted to those currently in a
methadone program;
• the processes used in the trial, particularly its service provision component. These processes could
also be described and assessed as outcome measures. This reflects the fact that, for many of the clients
and providers of drug treatment services, the quality of the interpersonal interaction in the service is
significant in its own right, as well as being a factor influencing retention rates.
It was also suggested that the trial could have both negotiable and non–negotiable outcome measures. In
other words, to be eligible to enter the trial, potential participants would have to agree to provide certain
information, and agree that the researchers could obtain specified information from third parties. The
latter could include surveillance data from official sources. Accessing other specified outcome indicators
could be a matter for negotiation. Obtaining information from friends and relatives could fall into this
category.
8 Non–Experimental Designs
Although most of the discussion at the workshop focused upon the experimental designs discussed
above, some consideration was also given to non–experimental approaches. As touched upon above, the
basic concept put forward was whether individual heroin users in Canberra should be the unit of analysis
in the research, or whether the focus would be better placed on the Canberra community as an entity, or
on Canberra heroin users as a community. (It was pointed out that there is no real ‘community’ of heroin
users in Canberra. Rather, there are a number of networks of users and the members of different
networks often do not interact intensively.)
Discussion revolved around the need to clarify the research question. For some members of the public
and decision makers, the key question could be something like ‘what is the likely impact on the Canberra
heroin–using community of making the drug available in a manner different from the way it is at
present?’. The outcome measures that would flow from such an approach would be primarily at the
community–wide level (as discussed above), rather than relating to the functioning of individual trial
participants. This is a complex research question, one that does not lend itself nicely to experimental
research designs. (Adequately controlled comparisons of different regimes of heroin availability in
different Australian cities, an experimental approach using the community as the level of analysis, was
not considered feasible.) Focusing on the community rather than individual heroin users is also less
intrusive and recognises the potential vulnerability of individual users.
The quasi–experimental design of the ‘n=1’ variety was mentioned. In this approach, the Canberra
heroin–using community (or the total Canberra community) would be the unit of analysis. Measures
would be made of the nature of the community at Time 1, heroin would be made available in a controlled
manner for a period and the nature of the community at Time 2 would be assessed and differences
between Time 1 and Time 2 observed. This would be a prospective design with an historical control. The
weakness of this design, it was agreed, is the multiple confounders of the measures: many changes could
occur in the community between Time 1 and Time 2, resulting from diverse influences. It would be
difficult or impossible to assess the changes caused by the changed availability of heroin. Most workshop
participants therefore favoured one of the experimental approaches discussed earlier.
Nevertheless, the discussion about non–experimental approaches was valuable in clarifying the
limitations of the experimental approaches. It threw into relief the limits of generalisability of an
experimentally based trial, the types of research questions that such a trial could ask and the units of
analysis for such a trial. The discussion also highlighted the political aspects of trial design and
evaluation and the need, at a minimum, to document political constraints. There was some discussion
about the extent to which trial design and evaluation should be influenced by political “realities”.
9 Conclusion
There was a level of agreement at the workshop that the unit of analysis should be heroin users willing to
enter treatment, rather than all heroin users, and that the primary research question should be concerned
with the quality of life of the trial participants. As discussed earlier, it was concluded that the results of an
experimentally based trial would be generalisable only to treatment programs that were similar to the
trial. An experimentally based trial would provide no information on other issues such as the likely
impact of controlled availability of heroin on the community generally, though such information could
possibly be gathered through research external to the trial.
Final decisions about trial design and evaluation cannot be made until research which is currently
underway is completed. This research allows for a more refined estimation of potential numbers of trial
participants and likely levels of health problems, HIV risk behaviours, criminal behaviours, illicit drug
use and social problems associated with heroin use among potential participants. This will determine
whether or not such variables can be used as outcome measures.
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AN EVALUATION OF POSSIBLE DESIGNS FOR A
HEROIN TRIAL
(DRAFT)
R.G. Jarrett & P.J. Solomon
Department of Statistics
University of Adelaide
16 August 1993
Abstract
This paper considers several alternative trial designs in the case where some participants elect not to have
certain treatments. It is shown that this necessarily leads to a 1oss of power, but that substantial improvements can
be made over the 'intention to treat' analysis. Two main designs are considered, with one showing a clear advantage
over the other.
1  Introduction
A trial to provide heroin in a controlled manner to dependent users must be rigorously designed,
conducted and evaluated.  During the Stage 1 feasibility investigations, it was proposed that this could
best be done in by providing heroin in a randomised controlled trial (Bammer et al., 1991).  However this
methodology has important limitations (Bammer, 1993).
In recent years there has been growing resistance by participants and, often, service providers to
randomised controlled trials.  This may manifest in refusal by service providers to allocate participants,
pooling of medications by participants and high drop-out rates.  A randomised controlled trial
comparing heroin and methadone has only been tried once before.  At that time injectable heroin was the
usual treatment and oral methadone the new alternative.  There was a high drop-out rate from the oral
methadone group.  Twelve percent of participants allocated to oral methadone left the trial immediately.
By three months less than 50% were still in the trial and by 12 months this had fallen to 29%.  At 12
months 74% of those in the heroin arm were still in the trial (Hartnoll et al., 1980).
More recently, traditional designs and conduct of randomised controlled trials have been challenged by
drug trials for the treatment of people with HIV disease.  The major issues and difficulties in this context,
and some suggestions for overcoming them, are discussed in Byar et al (1990) and in Green et al (1990).
The emphasis in rethinking is on making such trials flexible and acceptable to potential participants.
One flexible approach that has been tried is the use of subtrials.  In the AIDS trial 'Alpha', patients
intolerant of AZT were offered a choice of subtrials: patient choosing subtrial A were randomised onto
high DDI vs low DDI vs placebo; patients choosing subtrial B were randomised onto high DDI vs low
DDI.  However, the randomisation scheme did not work very well, in that very few participants opted for
the subtrial containing the placebo group and this arm of the trial was wound up early (personal
communication with Professor Peter Armitage).  The subtrial idea also comes in the cardiovascular trial
ISIS-3 (1992), where patients for whom physicians thought fibrinolytic therapy, was required were
randomised to streptkinase, tPA or APSAC, whereas those for whom the indication was 'uncertain' were
randomised to one of these three groups or to 'open control', but no placebo.
The use of subtrials in these contexts has motivated us to consider the prospect of their use for the heroin
trial.  This report details several options which are available for the conduct of the heroin trial.  These
options are based around the idea that it is expected that some participants will not agree to certain
treatments and that it is therefore important to allow a certain element of choice.
We will consider three different treatments to which participants may be allocated.  These will be referred
to as H (heroin only); H+M (heroin and methadone combined) and M (methadone only).
In looking at the comparison of treatments, we will suppose that each observation has a variance s2 and
that there are N participants altogether.  At this stage, we do not need to discuss what measurements are
actually being made on each participant.  The figures quoted will then be the standard deviations of
treatment estimates, ignoring the factor s/ÖN.  We will want this number to be as small as possible.
The most important treatment estimate to consider is the difference between the Methadone group (M)
and the Heroin group (H).  In all the models considered, the number of participants and the method of
allocation will be the same for both H and H+M, so that the comparison between the H+M and the M
groups will have the same accuracy.  We might expect that the comparison of the H and H+M groups
will be more accurate in general because of the way participants are allocated to those groups.
The baseline figure would be if we simply could randomly assign all N participants into three equal size
groups.  The result would be a variance for the treatment differences of 6s2/N, so the standard deviation
figure ignoring the factor s/ÖN is Ö6 = 2.449.  We will use the symbol R to denote the figure we get from
various designs, remembering that R = 2.449 is the best we can hope for.
The analysis at this stage will make several simplifying assumptions which will be outlined in the course
of this paper.  A more thorough study will have to address these issues and would be necessary before
the results can be published.  We do not, however, believe that these assumptions will materially alter the
results contained in this report.
2  Design I
If the participant is suitable for the trial, we would first ask whether the participant is prepared to accept
a treatment which does not involve the use of heroin.  If the answer is NO, they go into Group I; if YES,
they go into Group II. (It is possible that there will be a Group III consisting of those who will only accept
NON-heroin treatments or in fact the H group alone.) The treatment allocation can then be pictured as:
H               H+M M
------------------------------------------------------------------------------
Group I A   B
Group II   C D
------------------------------------------------------------------------------
and we might put N/4 of the N participants into each of the 4 possibilities.  Since there is randomization
into the two treatment choices within each of the groups, the treatment comparisons within Group I and
within Group II are valid.  However, comparisons across the groups cannot be justified on a
randomization argument because of the self-selection of participants into the two groups.  It is possible to
make a comparison between the two H+M groups, since they have the same treatment regime, so that
any difference can be ascribed to the bias caused by the element of self-assignment.  The difference
between these two groups can be regarded as the bias which needs to be corrected.  If we let the baseline
reading be a, the difference between the H and the H+M groups be b. the effect of self-selection be c, and
the difference between the H and M groups be d, the expected values in the four cells are:
H      H+M     M
-----------------------------------------------------------------------------
Group I a a+b
Group II a+b+c a+d+c
-----------------------------------------------------------------------------
Labelling the four treatment regimes above A, B, C and D, we can say that the estimate of the difference d
between Heroin and Methadone would be estimated by,
(A - B) + (C - D),
where the difference (B - C) corrects for the bias, just as a covariate would.  Each mean has a variance of
4s2 /N, so the variance of this combination of means is given by 16s2 /N.  Thus, the ideal figure for the
standard error of the estimate of 2.449 mentioned above has been increased to 4.00.
Note that this value would be increased if
· the ratio of sample sizes A : B or C : D differed from 1: 1;
· the choice for insisting on heroin in the treatment differed from 50%.
We need to explore this further as there may only be 10%, say, who insist on having heroin in the treatment and we
would then only get 5% of all the patients having the first treatment regime.
Suppose that a proportion p of the N insist on having heroin (i.e. being in Group I). The optimal allocation
to minimize the variance above is to have proportions p/2 in each of A and B, and (1 - p)/2 in each of C
and D. The variance above then becomes 4s2/ {Np(1 - P)}, which gives a value of R which is very close to
4 for reasonable departures of p from 50%.  For example, at p = 0.20, we get 5.00, and at p = 0.10 it
increases to 6.67.
If p is large, we have an unavoidable problem because we simply cannot get many, patients into the M
group no matter what we do.  However, if p is small, the current design allocates very few to the H
group, and this is avoidable.  One way to do this is to allocate the Group II participants to all three of the
treatments rather than just to the H+M and M treatments and this is the participant of the next section.
3  Design II
3.1 The Model
We will again use as our benchmark the comparison of the H group with the M group.  In this case,
suppose that a proportion p opt for heroin only (i.e. H or H+M) and the remainder don’t mind.  We now
have to consider (i) the subdivision of each of Group I and II into the treatment regimes, and (ii) the
estimation of the difference between the estimates of H and the estimate of M.
The layout now has 5 possible treatment groups, the 4 given in the previous section plus a fifth one that
we will label E:
H H+M M
-----------------------------------------------------------------------
Group I A    B
Group II E    C D
-----------------------------------------------------------------------
Again, we use as our model an additive model whereby there is a "block" difference between Group I and
Group II, plus treatment effects corresponding to the three treatment regimes.  Our model then is that the
fitted values look like:
H     H+M M
-----------------------------------------------------------------------
Group I  a   a+b
Group II a+c a+b+c      a+d+c
-----------------------------------------------------------------------
and we are interested in the estimate of d, the difference between Heroin and Methadone, unencumbered
by the difference c between the groups.
Clearly, one estimate of this is just D - E and this is valid due to the randomization.  If, however, we want
to avail ourselves of the information in Group I, we can estimate b and c and hence arrive at a solution.
For simplicity, we will assume that we divide Group I equally between the two treatments, and for
Group II we choose a proportion (1 - f) to get Methadone only, and divide the rest equally between the
other two groups.  The proportions are then:
H H+M      M
----------------------------------------------------------------------------------------------
Group I p/2 p/2
Group II (1-p)f/2        (1-p)f/2 (1-p)(1-f)
----------------------------------------------------------------------------------------------
and we can now work out the estimates and the variances.
3.2 The Analysis
As a starting point, we note that
Var ( D – E ) = 
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but this ignores the information in groups A and B. If p were zero, this would of course do very well, and
we could get our figure slightly below 2.449 by a suitable choice of f. There are 5 group means and 4
parameters to estimate here, so we can find a more accurate estimate by performing a least squares
analysis of the model given above.  Details of these calculations will be given in an Appendix.  After some
calculation, we arrive at the formula for the variance as
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We note the similarity to the previous variance, particularly that this variance is necessarily smaller
unless p = 0.
Apart from the factor s2/N which we ignore for the moment, we can calculate this for any given value of
p and f. The results shown in Table 1, represent R; that is, we drop the factor s2/N from the formula and
then take the square root.  Clearly, by symmetry, the comparison of M with H+M would have the same
variance.  The accompanying Figure 1 shows the plot of these values, with increasing values of p from 0
to 0.9 given by the different curves, starting at the bottom of the graph with p = 0.
The conclusion is that the standard deviation is heavily influenced by p, high values of p giving much
higher standard errors for the treatment comparisons.  However, for a given value of p, the standard
deviation is very robust to different values of f, with any value between 0.3 and 0.8 being acceptable.  The
best value for f is around 0.60 when p is small, but is closer to 0.50 as p increases.  The increase in the
standard deviation as p increases is small, being only a 10% increase when p is as high as 30%.
Table 1: standard deviation of estimate (H-M) given the proportion "p" insisting on heroin and the
proportion "f" of the remainder who are divided equally into H and H+M.
Proportion insisting on heroin
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0.05 6.407 5.503 5.521 5.750 6.117 6.634 7.365 8.460 10.320 14.548
0.10 4.595 4.196 4.179 4.310 4.549 4.903 5.417 6.197   7.535 10.593
0.15 3.809 3.601 3.596 3.698 3.888 4.174 4.596 5.243   6.358   8.918
0.20 3.354 3.243 3.254 3.347 3.513 3.764 4.135 4.706   5.696   7.974
0.25 3.055 3.000 3.028 3.118 3.272 3.502 3.842 4.367   5.277   7.377
   0.30 2.845 2.827 2.868 2.960 3.108 3.326 3.646 4.140   4.997   6.978
   0.35 2.693 2.701 2.753 2.849 2.994 3.205 3.513 3.987   4.809   6.710
   0.40 2.582 2.608 2.670 2.771 2.917 3.124 3.425 3.887   4.687   6.537
f    0.45 2.503 2.544 2.615 2.720 2.868 3.076 3.374 3.830   4.618   6.439
   0.50 2.449 2.503 2.582 2.693 2.845 3.055 3.354 3.809   4.595   6.407
   0.55 2.420 2.484 2.572 2.689 2.847 3.061 3.365 3.824   4.615   6.438
   0.60 2.415 2.488 2.584 2.709 2.874 3.096 3.407 3.876   4.682   6.535
   0.65 2.436 2.519 2.624 2.758 2.931 3.163 3.486 3.971   4.801   6.708
   0.70 2.488 2.581 2.696 2.841 3.026 3.271 3.611 4.120   4.987   6.975
   0.75 2.582 2.686 2.814 2.972 3.173 3.436 3.801 4.343   5.265   7.373
   0.80 2.739 2.857 3.000 3.177 3.399 3.689 4.088 4.679   5.683   7.970
   0.85 3.003 3.142 3.308 3.510 3.764 4.095 4.547 5.214   6.344   8.913
   0.90 3.496 3.667 3.870 4.117 4.425 4.824 5.368 6.170   7.522 10.589
   0.95 4.702 4.944 5.230 5.578 6.010 6.567 7.325 8.437 10.309 14.544
3.3 An Example
One way to use this table is to consider how much the sample size would have to increase to produce the
figure 2.449. The answer to this is the square of the ratio of the two numbers.  Thus, if p = 0.4, 40% of the
participants decline the Methadone only treatment and our best value of f is 0.50. The proportions in the
groups are then:
H              H+M M
------------------------------------------------------------------------
Group I 0.2 0.2
Group II 0.15 0.15 0.3
-----------------------------------------------------------------------
We then obtain R = 2.845. To achieve the same accuracy from the experiment as we would have got with
p = 0, we need to increase our sample size from N to N(2.845/2.449)2 = 1.35N. Thus, we would need 35%
more participants to achieve the same accuracy as the p = 0 case.  Of course, if we assumed p = 0 by not
asking, the variance in the M group would increase because some participants would opt out and seek
other sources of heroin.
4 Design III
The alternative is to consider properly randomised designs in which we then give some participants
choice as to whether they opt out of a particular treatment.  The scenario here is that we explain to
participants about the clinical trial and the three possible treatments.  They are told that they will be
allocated to one of the three treatments but that, if they are allocated to methadone only (M), they will
have the option to refuse and be switched to one of the other treatments.  If they choose this option, they
would be randomized to either H or H+M.
4.1 The Layout
This produces a design very similar to the second option above.  We can produce the same layout into 5
treatment classes, but Group I now corresponds only to those people who were first allocated to M and
then revealed that they would not accept M.  Others who not accept M are now allocated directly to H or
H+M and never asked about their preferences.  In the table below, E and C represent the groups initially
randomized into H and H+M.  The group assigned to M are then given the choice of opting out; we
assume a proportion p do so, and are randomly assigned (in equal proportions) to A and B; those who do
not opt out remain as Group D:
H H+M M
-----------------------------------------------------------------------
Group I A    B
Group II E    C D
-----------------------------------------------------------------------
The decision we have to make is what proportions are allocated to the 3 groups initially. We will suppose
that a proportion f/2 are allocated to each of E and C, and the remaining proportion (1-f) are allocated to
Methadone.  This leads to the following proportions in the groups:
H        H+M M
--------------------------------------------------------------------------------------
Group I p(1-f)/2     p(1-f)/2
Group II   f/2      f/2 (1-p)(1-f)
----------------------------------------------------------------------------------------
There are two ways to analyse this trial.  The first is to fit a model similar to that in Design II, where we fit
a linear model to the 5 groups formed, assuming as before that there is a difference between the heroin
based groups according to whether they accept or decline to be in the Methadone group.  The second
method is to do it according to the "intention to treat", so that we just consider the three groups formed
by the initial randomization.  It follows that the Methadone group will in fact be a mixture of results from
all three treatments, with the consequent loss of power, particularly when p, the proportion opting out of
Methadone, is large.
4.2 The Model
As a first step, we consider the same model as for the previous design, namely that
· those in the H+M group have a mean which is higher by b than those in the H+M group,
· those who would be prepared to be in the M group have a mean higher by c than those who would (if
asked) have opted out of the M only treatment, and
· those in the M group have a mean higher by d than those who are in the H group and who would have
agreed to be in the M group (if asked).
Again, our primary interest will centre on estimating the parameter d. To obtain the expected values in
the groups, we note that both E and C are in fact a mixture of two sets of participants, namely a
proportion p who would have declined to be in the M group had they been offered it, and a proportion
(1- p) who would have accepted the M group if offered.  They were not, given the choice.  The reality is
that the number who would have made each choice has a binomial distribution with these proportions.
In our calculations, we assume it is exactly a proportion p. Then the mean for Group E, for example is
given by
p   ´ a + (1 - p)  ´(a + c) = a + c(1 - p),
while for Group C it is a + b + c(1 - p).  Thus, the table of means for the 5 groups is
H     H+M M
 ---------------------------------------------------------------------------
Group I  a    a+b
Group II a+c(l-p)    a+b+c(l-p) a+c+d
----------------------------------------------------------------------------
with the proportions given above.  The mixtures in Groups C and E imply an increase in variance.  For
Group E, a proportion p have mean a and a proportion (1 - p) have mean a + c. This implies that the
variance of a single observation is increased from the usual s2 to s2+ c2p(1 - p).
The same variance applies to a single observation from group c. Since the distribution of values from
these groups is a mixture of two normal distributions, the variance does not decrease in the usual way as
we take more observations and take a mean.  In very large samples, for example, we will have a
concentration of values about the two separate values corresponding to the two types of observations
making up the group.  Hence, when there are n participants with the proportions in each group as above,
the variances of the group means will be
Var(C) = Var(E) = 2s2 /(N f) + c2p(1 - p).
We do not pursue this here, and will work on the basis that c is small while arguing that it should be
included in the estimation procedure.
4.3 The Analysis
Now we can argue here for two approximations.  The first is that, unless we ask who would or who
wouldn't have accepted the M group allocation, the sample variances calculated in each group don't
contain much information about the value of c.  We would need large sample sizes for this to be useful, as
such information would rely on the ratio of two sample variances , which are generally highly variable.
The second is that we will assume for the present that c is small relative to the other effects and hence
that, unless N is large, the effect of c on the variance of the group mean is marginal.  Suppose for example
that p = f = 0.5 and that c = 0.5s. Then the variance of the group mean for E is increased by a factor 1 +
N/64.  If we run a trial with several hundred people, this will severely reduce the accuracy of these two
group means and will mean the results that follow would need to be reworked.  For the moment we
ignore this effect.
With these two simplifying assumptions, we may proceed to the least squares analysis.  The variances of
the group means are s2 /N divided by, the proportions allocated to each of the five groups.  We then find
that the variance of d is given by
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which can be shown, for given p and f to be necessarily larger than the formula given for Design II. This
does not necessarily matter because we may well choose to use a different f for this design.  However, it
does imply that, for any given p, we can choose an f  which will give a lower variance.  Table 2 shows the
values for a range of p and f, and Figure 2 is a graph of the same values with p increasing from 0 in the
bottom curve to 0.9 for the top curve.
4.4 An Example
Consider the same example.  If we think that p is about 0.4, we would use f = 0.5 anyway.  Thus, initially,
we allocate 25% of the participants to each of H and H+M, and 50% to the M group.  If 40% of the M
group opt out and get allocated to the other groups, the final allocation is:
  H         H+M M
------------------------------------------------------------------------------------
Group I 0.15 0.15
Group II 0.25 0.25 0.20
------------------------------------------------------------------------------------
The value of R is 3.541, so the sample size has to increase to 2.09N, even larger than before.
TABLE 2: Standard deviation of estimate (H-M) in Design III, given the proportion "p" insisting on heroin
and the proportion "f" of the remainder who are divided equally into H and H+M (Least Squares model).
Proportion "p" insisting on heroin
f 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0.05 6.407 5.735 6.088 6.779 7.798 9.280 11.541 15.340 22.968 45.895
0.10 4.595 4.357 4.575 5.038 5.748 6.802   8.427 11.173 16.703 33.350
0.15 3.809 3.733 3.922 4.298 4.881 5.754   7.109   9.407 14.046 28.025
0.20 3.354 3.360 3.542 3.877 4.391 5.164   6.367   8.412 12.548 25.022
0.25 3.055 3.108 3.291 3.604 4.078 4.789   5.896   7.781 11.598 23.117
0.30 2.845 2.929 3.117 3.417 3.867 4.537   5.581   7.360 10.964 21.846
0.35 2.693 2.799 2.992 3.287 3.721 4.366   5.369   7.077 10.538 20.991
0.40 2.582 2.705 2.904 3.198 3.624 4.254   5.230   6.893 10.262 20.438
0.45 2.503 2.640 2.846 3.142 3.566 4.188   5.151   6.789 10.106 20.127
0.50 2.449 2.599 2.814 3.115 3.541 4.163   5.123   6.754 10.055 20.026
0.55 2.420 2.582 2.806 3.115 3.549 4.178   5.145   6.786 10.105 20.127
0.60 2.415 2.590 2.825 3.145 3.590 4.233   5.218   6.887 10.259 20.438
0.65 2.436 2.624 2.874 3.209 3.671 4.335   5.351   7.068 10.534 20.990
0.70 2.488 2.692 2.959 3.314 3.801 4.497   5.559   7.349 10.960 21.845
0.75 2.582 2.806 3.096 3.478 3.999 4.741   5.869   7.768 11.592 23.116
0.80 2.739 2.989 3.310 3.731 4.301 5.110   6.336   8.397 12.542 25.020
0.85 3.003 3.292 3.659 4.138 4.784 5.697   7.077   9.391 14.040 28.024
0.90 3.496 3.849 4.295 4.874 5.650 6.745   8.396 11.157 16.697 33.348
0.95 4.702 5.200 5.825 6.633 7.714 9.232 11.515 15.328 22.964 45.894
4.5 Intention to Treat
An alternative analysis here is to ignore the randomisation at the second stage and simply to analyse the
data on the basis of the original randomization; that is, on the basis of the intention to treat.  This will
necessarily throw away known information since we do know what treatments the participants
eventually had, whereas the intention to treat usually works on the basis that we don't really know who
used what in the M group.  We would therefore expect the variances to be larger.
To do this, we need to combine groups A, B and D and consider them as one group.  This leads to the
following expected values:
 E C                F={A,B,D}
------------------------------------------------------------------------------------------------------
Mean a+c(1-p) a+b+c(1-p) a+c(1-p)+pb/2+(1-p)d
Propn f/2                f/2               (1-f)
------------------------------------------------------------------------------------------------------
From this we see that we cannot distinguish any more between a and c, and there are three means which
essentially depend on only three parameters.  Our solutions are therefore given by
           a+c(1-p) = E
         b = C-E
           d = {F-pC/2-(1-p/2)E}/(1-p)
where C, E and F represent the mean values for each group.  Note that, as mentioned earlier, the mixing
of groups with different means leads to additional variation for the mean that does not decrease as N gets
larger.  If, however, we again ignore this portion of the variation, we can evaluate the variance of this
linear combination and obtain:
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which again can be shown to be larger than the previous formulae.  The results for this are in Table 3, and
are depicted graphically in Figure 3.
TABLE 3: Standard deviation of estimate (H-M) in Design III, given the proportion "p" insisting on heroin
and the proportion "f" of the remainder who are divided equally into H and H+M (Intention to Treat
model) .
Proportion "p" insisting on heroin
f 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0.05 6.407 6.782 7.273 7.935 8.859 10-208 12.312 15.935 23.373 46.101
0.10 4.595 4.870 5.231 5.716 6.393 7.379 8.913 11.552 16.964 33.483
0.15 3.809 4.043 4.350 4.762 5.334 6.168 7.462 9.686 14.239 28.124
0.20 3.354 3.566 3.843 4.214 4.729 5.477 6.638 8.628 12.698 25.100
0.25 3.055 3.253 3.512 3.858 4.338 5.033 6.110 7.954 11.719 23.180
0.30 2.845 3.035 3.282 3.613 4.070 4.731 5.753 7.500 11.063 21.898
0.35 2.693 2.878 3.119 3.439 3.882 4.521 5.507 7.190 10.618 21.034
0.40 2.582 2.765 3.002 3.317 3.752 4.378 5.342 6.985 10.328 20.474
0.45 2.503 2.685 2.922 3.235 3.667 4.288 5.242 6.864 10.160 20.156
0.50 2.449 2.634 2.872 3.188 3.621 4.243 5.196 6.815 10.100 20.050
0.55 2.420 2.609 2.852 3.172 3.611 4.240 5.203 6.835 10.140 20.146
0.60 2.415 2.610 2.860 3.189 3.639 4.282 5.264 6.926 10.288 20.453
0.65 2.436 2.639 2.899 3.242 3.708 4.373 5.386 7.098 10.556 21.002
0.70 2.488 2.703 2.978 3.339 3.828 4.525 5.585 7.371 10.976 21.854
0.75 2.582 2.814 3.109 3.495 4.018 4.761 5.888 7.784 11.605 23.123
0.80 2.739 2.994 3.319 3.742 4.314 5.123 6.349 8.408 12.550 5.025
0.85 3.003 3.295 3.665 4.145 4.792 5.705 7.085 9.398 14.045 28.027
0.90 3.496 3.851 4.298 4.877 5.655 6.749. 8.400 11.161 16.700 33.350
0.95 4.702 5.200 5.826 6.635 7.716 9.234 11.517 15.329 22.965 45.895
5 Conclusions
Figure 4 shows the actual randomization scheme used for Design II and Design III (indicated there as
Solution 1 and Solution 2) and makes clear the differences between them.
The conclusions reached are the following:
· It is clear that as soon as we have some participants declining particular treatments, we have an
increased standard deviation for comparisons; this is the same as a loss of power - that power can only be
regained by increasing the sample size.
· When participants decline particular treatments, we cannot assume that their final outcome
measurements will follow the same pattern as those who do not decline those treatments.  This study
supposes that there is a shift in the mean between those two groups.
· The loss of power occurs most rapidly using the Intention to Treat model for Design III.  This is because
the analysis does not utilise known information about which participants chose which treatments.
· Design II and Design III are essentially giving similar results.  In practice we will not know what the
value of p is prior to starting the experiment, so it would be wise to choose a value of f which is
conservative in the sense of affording protection against a larger rather than a smaller value of p. A value
close to 0.50 appears to be the best value to take.
· The analysis shows a preference for Design II as p gets larger.  Once p is about 0.4, Design III needs 50%
more participants (compare the figures 2.09N and 1.35N above) to achieve the same power.
· The question which must be considered is whether the linear model is suitable (on some scale) for the
outcome measures envisaged for this experiment.  If the outcome measure is related to the time taken to
some event, then the linear model might well apply, as in a Cox model to the log hazard.
· The current analysis is incomplete for several reasons.  The crucial assumption is that we have ignored
the effect on the variance of group means caused by the fact that they are often mixtures of observations
from different groups.  This will inflate the estimates of variance for Design III, which is where this
happens, for both the ordinary analysis and the intention to treat analysis.  More work needs to be done
on this aspect.  This suggests that Design II is a preferable scenario.  Design II is essentially running two
separate trials but attempting to combine the result afterwards.
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Figure 4
SOME POSSIBILITIES FOR HEROIN TRIAL
SCENARIO: Three possible treatments: Heroin, Heroin + Methadone, Methadone only.
PROBLEM: Some potential participants will not accept Methadone only.
SOLUTION 1: Find out which first, then randomize.
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1 Introduction
This discussion paper raises for consideration issues concerned with service provision within a
proposed trial of controlled availability of heroin. The thesis of this paper is that while we
recognise the strengths of a randomised controlled trial in answering certain types of research
questions, there are service provision concerns of trial participants (both staff and heroin users)
that may be inconsistent with standard RCT designs. These concerns relate to the effectiveness of
service provision. There is widespread concern about the effectiveness of health care services
generally, both in relation to successful outcomes and cost effectiveness. With regard to service
provision for drug users, there is generally considered to be considerable room for improvement in
both prevention and treatment strategies. We reflect here on the principles we consider would
underlie the provision of an effective service in the context of the controlled availability of heroin.
They constitute a health development approach.
What are the objectives of the research? The research question can be conceived as something like
‘Does the controlled availability of heroin result in less harm than the current uncontrolled
availability?’. We prefer, however, a formulation more like ‘What are the conditions under which
the controlled availability of heroin will result in less harm than the current uncontrolled
availability?’. Does this imply a more complex trial design?
This research question is quite different from that which is currently conceived to underlie a ran-
domised controlled trial. The most important difference is the importance placed on the context in
which the controlled availability of heroin occurs, that is, ‘What are the conditions under which...’
Stating the research question this way also begs questions about what we mean by ‘harm’. We note
that there are many different ways of constructing drug–related harm, and that drug related harm
cannot be seen in isolation from drug policy. Some constructions reflect the chemistry of the drugs
themselves. Others reflect characteristics of users. Still others reflect the illegal status of some
drugs and society’s responses to their illegality. The trial design will need to enable assessment of
harm reduction in a number of areas concurrently. However, the ability to change drug policy (or
not) may be a major constraint on the extent to which drug–related harm can be ameliorated.
2 Issues for all RCTs that are especially relevant here
A number of issues applying to all RCTs form a backdrop to the consideration of service provision
in a ‘heroin trial’. They include the following:
• the RCT is most effective when it is testing a clear, preferably single, hypothesis. It is not so
well suited to assessing the outcomes of complex interventions, including policy–related
interventions like the controlled availability of heroin, particularly if the service delivery
context in which the controlled availability occurs is different from that of conventional
services;
• the design must be feasible. Heroin users are telling us what they want in a trial’s service
provision and the characteristics that will deter them from participation. Will they accept
randomisation to an arm that does not provide heroin?;
• ethically, we cannot proceed with a RCT unless we are convinced that the design has sufficient
statistical power to answer the research questions. How far do service provision considerations
impact on this? Can we identify a design that can encompass the service provision realities?;
• the ethics of randomisation. A conundrum for all RCTs is that the whole basis for the RCT is
that there is some evidence that the new ‘thing’ being tested has some chance of success at least
for some people. Therefore, RCTs that are not conducted ‘blind’ can present difficult problems
for service providers and participants who may have particular beliefs that one arm is likely to
be of more benefit than another. They may feel that random allocation is unethical. An example
may be useful here. What if an individual who is known to have done badly on methadone in
the past is randomly allocated to the methadone group, when both that person and the service
providers believe that the individual would do well on heroin? Almost certainly, allocation in
the proposed trial will be unblinded and staff will be aware of participants’ history, allocation
and progress throughout the trial;
• generalisability. To obtain successful control, trials sometimes need to be far removed from
everyday conditions, resulting in findings that are not generalisable. However, this research
needs to be policy–  and program– relevant and to answer important topical questions.
3 Principles of practice and how they contribute to health
development
Without being prescriptive or comprehensive, we wish to give readers, particularly those with
limited previous contact with heroin users and drug treatment agencies, some feel for the types of
principles that we see as underlying a service provision model. Some are innovative, while others
are seen in the operation of existing agencies. Some are well understood and apparently accepted
by service staff and/or clients, but, for a variety of reasons, are not implemented. We then tie each
group of principles to a concept of health development. The grouping is somewhat arbitrary as
most service provision principles cut across each of the health development principles. The health
development concepts arise from a broader program of research being undertaken by one of us
(DL).
The first group of principles of service provision is that:
• clients have various ways of understanding their own drug use; these need to be respected and
a service should not impose any particular theoretical understanding on the client;
• clients should determine their own desirable service outcomes;
• the quality of the relationship between staff and clients counts;
• the service will not judge the morality of the pleasurable aspects of drug use;
• individual differences will be recognised and fostered;
• nothing about the service should exacerbate the social marginality of many heroin users;
• clients have a right to have children.
These illustrate the health development principle that the service delivery is undertaken in a
respectful collaboration with the people whose health it is (at both the clinical and community
levels).
The second group of principles of service provision is that:
• the service should contribute to redressing the structural causes of the problems with which the
clients present;
• there should be respect for the client’s view of the link between the presenting problems and
the structural causes of those problems;
• the concept of illegality based harm (as well as drug based harm) is valid;
• a plurality of reasons for drug use exist.
These illustrate the health development principle that the service delivery addresses the micro and
immediate needs of sick care and public health in ways that also contribute to redressing problems
understood in terms of macro level structures and longer time horizons.
The third group of principles of service provision is that:
• the service should foster social integration as it is perceived by the client;
• the service should encourage personal responsibility.
These illustrate the health development principle that the service delivery addresses the technical
tasks of sick care and public health in ways that also strengthen our ability to manage existential
challenges.
The fourth group of principles of service provision is that:
• society is providing a service to users and users have a responsibility to society in return;
• clients should be encouraged and given opportunities to be involved in the development of
and management of the service, collaboratively with clinical and administrative staff;
• the principles of service operation should be explicit.
These illustrate the health development principle that the service delivery conceives the functions
of sick care and public health as continuous with the broader domains of living a fulfilling life and
contributing to building a better society.
We are seeking to use both the service provision and health development principles to develop a model of
service provision for a trial that will contribute to harm reduction through impacting on a range of determinants
of harm, rather than just providing heroin in a safe controlled manner. Obviously, a RCT could go ahead in a
manner that does not reflect these principles, but reproduces the stigmatising and controlling nature of too many
contemporary services for heroin users. However, such an approach may well not contribute greatly to reducing
harm.
4 Conclusion
Two possible outcomes from these considerations are to replace the RCT design or to further
modify it.
With regard to modification of an RCT, we see a number of issues as problematic. Two issues that
are particularly important, and are good illustrations of the difficulties inherent in an RCT, are
client choice and individualised treatment.
Client choice. Some participants will want to move between the arms of a trial as it and they
progress, and this needs to be allowed for. An example might be a person in the methadone only
arm who has been doing well until faced by a crisis (such as the death of a loved one). The par-
ticipant wants to start using heroin again to better numb the pain. Can they move arms or should
they be forced back to street heroin?
Individualised treatment. Problems can arise when trial restrictions, or rules made to protect staff
or clients, or laws conflict with what clients see as serving their own needs. To some extent these
can be overcome with individualised treatment. Two examples illustrate this. First is the
participant in the methadone arm who is continuing to use large amounts of street heroin. Should
staff simply view this as a trial outcome or try to intervene? The second example is that in current
methadone programs, a large percentage of clients have access to take–away doses. Take–aways
are likely to be a problem for a heroin trial, both because of the perception of the risks of diversion
and because trial participants may become the targets of violence. Should this mean that, for the
sake of comparability, participants in the ‘methadone arm’ should also be refused take–aways?
Should it mean that participants in the ‘heroin arm’ should have restrictions placed on their ability
to leave the ACT for holidays, or to visit sick relatives, or even to stay at home in bed when they
are ill?
We have raised for discussion issues concerned with the service provision features of a trial. This
reflects our view that a trial is important in seeking to answer questions about the impact of the
controlled availability of heroin and that the quality of service provision within the trial is also
crucial for its effectiveness and for ethical and practical reasons.
The final proposal for the design and evaluation of a ‘heroin trial’ must address the dilemmas we
have raised.
FEASIBILITY RESEARCH INTO THE CONTROLLED AVAILABILITY OF
OPIOIDS
The Feasibility Research into the Controlled Availability of Opioids arose from a request to the
National Centre for Epidemiology and Population Health (NCEPH) from the Select Committee on
HIV, Illegal Drugs and Prostitution established by the Australian Capital Territory (ACT)
Legislative Assembly.
A first stage of research, conducted in collaboration with the Australian Institute of Criminology
(AIC), found that a trial to provide opioids, including heroin, to dependent users was feasible in
principle. It was recommended that a second stage of feasibility investigations to examine logistic
issues be conducted.
The first stage investigations examined illegal drug use in the ACT, the arguments for and against
the controlled availability of opioids as reviewed in the literature, the current Australian political
context for a trial, the role of interest groups in social controversies, legal issues, possible options
for a trial, ethical issues, attitudes to a trial in the general community and among key interest
groups (police, service providers, and illegal drug users and ex–users), and evaluation by a
randomised controlled trial.
In addition, a proposal for a trial was developed as the starting point for the Stage 2 investigations.
The research which needs to be conducted to determine Stage 2 logistic feasibility can be divided
into five areas:
• core information (for example, estimating numbers of users, determining relevant char-
acteristics of ACT–based users, documenting the known information about the psy-
chopharmacological and toxicological effects of opioids);
• information relevant to trial design and evaluation;
• information relevant to service provision;
• information about relevant legal, law enforcement and criminological matters; and
• community and key stakeholder acceptability of a specific trial proposal.
The Stage 2 research is also governed by the following principles:
• the research should have intrinsic value so that, regardless of whether or not a trial goes
ahead, the research should be of value to treatment services or to drug policy generally;
• research should be conducted in all relevant disciplines and the disciplinary findings
should be integrated to address the central problem;
• the process should involve to the greatest extent possible the key interest groups— illicit
drug users, ex–users, service providers, police, policy makers and the community.
Stage 2 of the feasibility research into the controlled availability of opioids has many components.
As significant advances are made in each particular substudy, we publish the results as a working
paper, so that the information is available for discussion in the public arena.
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